[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594627":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":10,"centralContacts":32,"locations":38,"responsibleParty":55,"collaborators":10,"id":57,"slug":10,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Campus Bio-Medico","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"ADC's group",null,"Patients undergoing ADC's drugs such as Trastuzumab Emtansine (TDM1), Trastuzumab Deruxtecan, Sacituzumab Govitecan",[13],"Radiation: Radiotherapy",{"label":15,"type":10,"description":16,"interventionNames":17},"Cyclin-dependent kinases 4 and 6 inhibitors (CDK4\u002F6 group)","Patients receiving Palbociclib or Ribociclib or Abemaciclib",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Anti Human Epidermal Growth Factor Receptor 2 monoclonal antibodies (Anti-Her2 group)","Patients receiving Trastuzumab or Trastuzumab Pertuzumab",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"IT group","Patients receiving Atezolizumab or Pembrolizumab",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":10},"RADIATION","Radiotherapy","Conventional fractionated radiotherapy, moderate hypofractionated radiotherapy, stereotactic radiotherapy (SABR)",[9,19,15,23],[33],{"name":34,"role":35,"phone":36,"phoneExt":10,"email":37},"Edy Ippolito, Prof","CONTACT","06225418011","e.ippolito@unicampus.it",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":43,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Radiation Oncology Department Fondazione Policlinico Campus BioMedico","RECRUITING","Rome","Italy","00128","IT",{"type":47,"coordinates":48},"Point",[49,50],12.51133,41.89193,{"lat":50,"lon":49},[53],{"name":34,"role":35,"phone":54,"phoneExt":10,"email":37},"06\u002F225418011",{"type":56,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100594627",false,"NCT07021911","Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer","COMBaRT","Inclusion Criteria:\n\n* Patients suffering from stage IV breast cancer\n* Ongoing systemic treatment including: molecular targeted therapy, conjugated antibodies, monoclonal antibodies, tyrosine kinase inhibitors, immunotherapy (immunocheckpoint inhibitors)\n* Candidates for radiation treatment (both palliative and curative).\n\nExclusion Criteria:\n\n* Previous radiation treatment on the same site\n* Absolute contraindications to radiotherapy\n* Systemic treatment administered as part of a clinical trial","ALL","18 Years",{"count":66,"type":67},300,"ESTIMATED","OBSERVATIONAL","The primary objective of the study is to describe the tolerance profile of radiation treatments performed during systemic treatment with new drugs (molecular targeted therapies, immunotherapy, others).",[71,72],"Breast Cancer","Radiotherapy; Complications",[74,75,76,77],"breast cancer","radiotherapy","stereotactic radiotherapy (SABR)","side effects","2025-06-11",{"date":80,"type":81},"2025-06-15","ACTUAL",{"date":83,"type":81},"2023-05-17",{"date":85,"type":67},"2029-05-17",{"name":5,"class":6},1]